599 filings
Page 3 of 30
6-K
j9wbq lpbyhes96
1 Mar 23
Current report (foreign)
4:30pm
6-K
ae2e od7w848d4r
6 Jan 23
Current report (foreign)
4:49pm
6-K
rop 6ky5c47uz0fn
30 Nov 22
Current report (foreign)
9:08pm
6-K
z66t kwpfa
29 Nov 22
Current report (foreign)
4:58pm
6-K
i1cv4u1n22scfi
15 Nov 22
Current report (foreign)
4:43pm
6-K
1rlhyud20ch y938bn
9 Nov 22
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
4:01pm
6-K/A
sbp0jxfpfd8g 1g0aqf
12 Oct 22
Financial Statements for the years ended Report of Independent Registered Public Accounting Firm
5:45pm
6-K
j72agkjynzqh 8w
7 Oct 22
Notice of Annual General Meeting
3:06pm
6-K
9awh0dakte768avn
22 Sep 22
Current report (foreign)
4:07pm
6-K
k39ke93 yfvt8bmjla
14 Sep 22
Current report (foreign)
10:31am
6-K
wdwvtg 1y
29 Aug 22
Current report (foreign)
4:00pm
6-K
d2dh8 1f0dvgpxiu
19 Aug 22
Current report (foreign)
10:54am
424B5
n6i5vr4p 0t626cdt
19 Aug 22
Prospectus supplement for primary offering
10:52am
6-K
j3do3 74sn
1 Aug 22
Current report (foreign)
4:48pm
D
gg1e6kgb4l7qoanbum
29 Jul 22
$34.64M in equity, sold $34.64M, 4 investors
6:15pm
6-K
v2wm6cfsehqjj
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
9fdi ekx0mgz
8 Jul 22
Current report (foreign)
8:58am
6-K
0i02sf62mv61 ey
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
zdn n3noxy
23 Jun 22
Territory of the British Virgin Islands
4:05pm